Why The Ionis Pharma Spinoff Will Be A Win For Long-Term Investors

Published: Apr 19, 2017

Last month's announcement by Ionis Pharmaceuticals (NASDAQ:IONS) that the company was spinning off its Akcea subsidiary had some investors scratching their heads. Why was the company seemingly giving up so much for so little gain? It turns out that management has its focus squarely on the future, and long-term investors should be happy about the move.

Back to news